Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]
In development
Reference number: GID-TA11774
Expected publication date:
To appraise the clinical and cost effectiveness of Catumaxomab within its marketing authorisation for treating malignant ascites
ID6580